Bexorg is a technology company.
Bexorg has raised $23.0M across 1 funding round.
Bexorg has raised $23.0M in total across 1 funding round.
Bexorg has raised $23.0M in total across 1 funding round.
Bexorg's investors include Amplify Partners, The Engine.
Bexorg is a New Haven-based biotechnology startup revolutionizing central nervous system (CNS) drug discovery by using its proprietary BrainEx platform to study intact, metabolically active mammalian and human brains post-mortem.[1][2][6] The platform employs perfusion technology—combining artificial blood, a heart-lung-like device, and control software—to restore brain function for days, enabling precise imaging, pharmacokinetic analysis, and AI-driven data collection for therapies targeting diseases like Parkinson's.[1][2] Serving pharmaceutical companies and researchers, Bexorg solves the core problem of CNS clinical trial failures (over 90% historically) by bridging the translational gap between animal models, organoids, and human trials, generating petabyte-scale datasets for machine learning-accelerated drug development.[1][4][6] With $19.5 million raised, a Biohaven partnership, and scaling to 1,000 experiments annually, the company has grown from 5 to 30 employees in three years, positioning it as a high-momentum discovery engine for brain diseases.[2]
Bexorg emerged from a decade of Yale University neuroscience research in Nenad Sestan's lab, where limitations in studying large, dynamic brains stalled progress on human brain complexity.[1][2] Co-founder Zvonimir Vrselja, a physician and neuroscientist, collaborated with Sestan to invent the perfusion technology after hitting an impasse: traditional methods couldn't analyze metabolically active brains.[1] Initially developed for brain research and adapted for organ preservation, it spun out as Bexorg around 2022, with Vrselja as CEO and Sestan as co-founder; the company exited stealth in 2025 with a Biohaven partnership for drug testing.[2][4] Early traction included Nature publications validating the tech and rapid hiring of engineers, AI experts, and drug discovery specialists, fueled by $19.5M in funding and plans for more.[1][2]
Bexorg rides the convergence of AI-driven drug discovery, advanced biotech perfusion tech, and surging demand for human-relevant CNS models amid 90%+ trial failure rates for brain diseases.[1][2][6] Timing is ideal post-2020s AI boom and organoid limitations, amplified by market forces like aging populations driving Parkinson's and neurodegeneration needs, plus investor appetite for de-risking platforms (evidenced by Bexorg's funding and Biohaven deal).[2] It influences the ecosystem by "flipping drug discovery upside down," enabling pharma partnerships, proprietary pipelines, and foundational infrastructure for scalable brain research—potentially slashing development timelines and costs while broadening to organ donation viability.[1][2]
Bexorg is poised to dominate CNS drug discovery with BrainEx scaling to thousands of experiments, a new funding round, and expansion beyond Parkinson's to other brain disorders, leveraging AI for proprietary therapies.[1][2] Trends like multimodal AI datasets and human-tissue biobanking will propel it, evolving its influence from pioneer platform to ecosystem enabler—partnering with more pharmas and potentially licensing tech. As Vrselja envisions, this could realize "a world without brain diseases," transforming an impasse into an industry standard.[1]
Bexorg has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series A in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $23.0M Series A | Amplify Partners, The Engine |